Jon Congleton
Chief Executive Officer at Mineralys Therapeutics Inc.
Sits on 3 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 3 boards, counting each seat separately. Longest: Mineralys Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Mineralys Therapeutics Inc. May 22, 202487.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 13, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −10,700 | $27.24 | $291,441 |
| Jun 30, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −58,000 | $25.94 | $1,504,520 |
| Jun 30, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −17,000 | $26.82 | $455,940 |
| Apr 13, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −15,730 | $26.83 | $422,036 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −19,364 | $25.50 | $493,782 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −55,183 | $26.54 | $1,464,557 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −453 | $27.05 | $12,254 |
| Feb 19, 2026 | Mineralys Therapeutics Inc. | Grant or award | +140,900 | — | — |
| Jan 12, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −9,119 | $32.21 | $293,723 |
| Jan 12, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −7,117 | $33.15 | $235,929 |
| Nov 21, 2025 | Mineralys Therapeutics Inc. | Option exercise | +24,082 | $0.54 | $13,004 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −12,806 | $41.64 | $533,242 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −8,862 | $42.31 | $374,951 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −4,000 | $43.50 | $174,000 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −29,207 | $45.20 | $1,320,156 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.